Appl. No.: 10/591,895

Atty. Docket No.: NC-10006.US

REMARKS

Claims Status

Claims 1-3 and 16-30 are pending and are subject to restriction in the Office Action

mailed March 12, 2010.

Response to Restriction Requirement

The Office Action requires restriction under 35 USC § 121 among nine designated

groups of claimed subject matter. In response, Applicants hereby elect Group I defined as

compound and pharmaceutical composition Claims 1-3 and 17-25 of Formula I.

The Office Action requires election of a single species. In response, Applicants hereby

elect Example 18, the name and structure of which are given at p. 23 of the specification. The

claims readable thereon are believed to be at least Claims 1, 2, 17-23 and 25.

Applicants note that Groups I-IX encompass restriction between product and process

claims. Applicants respectfully request full rejoinder upon allowance.

CONCLUSION

The Examiner is welcome to call or otherwise contact the undersigned for any reason

pertaining this application.

Respectfully submitted,

/Jeffrey McQuiston/

Jeffrey M. Mcquiston Agent for Applicants

Reg. No. 63,109

Tel: (631) 962-2034

Fax: (631) 845-0582

Date: April 12, 2010
OSI Pharmaceuticals, Inc.
41 Pinelawn Road
Melville, NY 11747 USA